MIF and metabolic dysfunction-associated steatotic liver disease: In alignment with hepatic MIF knockdown, the effects of IPG1576 were more pronounced under MASLD conditions, highlighting the potential for personalized treatment in the subset of PDAC patients with MASLD (Fig. 5f, g, Supplementary Fig. 5i).